Investor Relations

Company Overview

Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).

Latest Financial Results

Q2 2022

Quarter Ended Jun 30, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Stock Information

IR Contacts

Company

Mustang Bio, Inc.
377 Plantation Street
1st Floor
Worcester, MA 01605
T: 781-652-4500

Investor Relations

IR@mustangbio.com